AffiliationDept of Radiotherapy, Royal Marsden NHS Foundation Trust, Sutton, UK
MetadataShow full item record
AbstractThe incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. Local treatments include surgery and radiotherapy and these are currently combined with (neo)adjuvant chemotherapy in specific cases to improve long-term outcome. Targeted therapies and immunotherapy may also become important therapeutic modalities in this patient group. For resectable disease in patients with low cardiopulmonary risk, complete surgical resection with lobectomy remains the gold standard. Minimally invasive techniques, conservative and sublobar resections are suitable for a subset of patients. Data are emerging that radiotherapy, especially stereotactic body radiation therapy, is a valid alternative in compromised patients who are high-risk candidates for surgery. Whether this is also true for good surgical candidates remains to be evaluated in randomised trials. In specific subgroups adjuvant chemotherapy has been shown to prolong survival; however, patient selection remains important. Neoadjuvant chemotherapy may yield similar results as adjuvant chemotherapy. The role of targeted therapies and immunotherapy in early stage nonsmall cell lung cancer has not yet been determined and results of randomised trials are awaited.
CitationManagement of stage I and II nonsmall cell lung cancer. 2017, 49(1): Eur Respir J
JournalThe European Respiratory Journal
- Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
- Authors: Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC
- Issue date: 2013 May
- Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
- Authors: Bunn PA Jr
- Issue date: 2004 Sep
- Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
- Authors: Logan DM, Lochrin CA, Darling G, Eady A, Newman TE, Evans WK
- Issue date: 1997 Dec
- Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
- Authors: Machtay M, Lee JH, Stevenson JP, Shrager JB, Algazy KM, Treat J, Kaiser LR
- Issue date: 2004 Jan
- Results of clinical trials of multimodality therapy for resectable nonsmall-cell lung cancer.
- Authors: Vallières E
- Issue date: 2003 Oct